✦ LIBER ✦

Gemcitabine (GEM) and docetaxel (DTX) salvage regimen in non-small cell lung cancer (NSCLC) failing prior paclitaxel platinum-based chemotherapy

✍ Scribed by C. Kosmas; N. Tsavaris; M. Vadiaka; N. Stavroyianni; A. Koutras; N. Malamos; A. Onyenadum; H. Kalofonos

Book ID: 117658050
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 168 KB
Volume: 37
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(01)80680-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gemcitabine and docetaxel as second-line

Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens

✍ Christos Kosmas; Nicolas Tsavaris; Maria Vadiaka; Niki Stavroyianni; Angelos Kou 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views

Combination chemotherapy with carboplati

Combination chemotherapy with carboplatin (CBDCA), docetaxel (DOC) and gemcitabine (GEM) in advanced non-small cell lung cancer (NSCLC). A phase II study

✍ Pectasides, D.; Aspropotamitis, A.; Halikia, A.; Visvikis, A.; Antoniou, F.; Kal 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 165 KB

Second-line docetaxel and gemcitabine co

Second-line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy

✍ Faruk Tas; Cumhur Demir; Hakan Camlica; Zeki Ustuner; Erkan Topuz 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 95 KB

Combined gemcitabine, ifosfamide and vin

Combined gemcitabine, ifosfamide and vinorelbine (GIN): activity and safety of a non-platinum-based regimen in advanced non-small-cell lung cancer (NSCLC)

✍ Baldini, E.; Ardizzoni, A.; Cafferata, M.A.; Del Freo, A.; Boni, L.; Tibaldi, C. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 165 KB

Gemcitabine and vinorelbine as second-li

Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens

✍ C Kosmas; N Tsavaris; C Panopoulos; M Vadiaka; N Stavroyianni; Th Kourelis; N Ma 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 116 KB

798 Impact of third line ZD 1839 therapy

798 Impact of third line ZD 1839 therapy on patients with advanced non-small cell lung cancer (NSCLC) who had failed prior platinum and/or docetaxel-based regimens (Astra Zeneca Expanded Access Programme)

✍ F. De Marinis; A. Mancuso; O. Martelli; M.R. Migliorino; R. Di Salvia 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 159 KB